DRUGSURV: A resource for repositioning of approved and experimental drugs in oncology based on patient survival information

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Amelio, I ^a   Gostev, M ^b   Knight, R A ^a   Willis, A E ^a   Melino, G ^a,c   Antonov, A V ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

clinical trial design; drug repositioning; patient survival; thioridazine

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER SURVIVAL; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG APPROVAL; DRUG COST; DRUG CYTOTOXICITY; DRUG REPOSITIONING; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG APPROVAL; DRUG EVALUATION; DRUG REPOSITIONING; HUMANS; INTERNET; NEOPLASMS;

EID: 84896775029     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.9     Document Type: Article

References (31)

1. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.
2. Jin G, Fu C, Zhao H, Cui K, Chang J, Wong ST. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 2012; 72: 33-44.
3. Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med 2012; 4: 27.
4. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010; 107: 14621-14626.
5. Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr. et al. In silico drug repositioning: What we need to know. Drug Discov Today 2013; 18: 110-115.
6. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690.
7. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A et al. DrugBank 3.0: A comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011; 39: D1035-D1041.
8. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO et al. An overview of the PubChem BioAssay resource. Nucleic Acids Res 2010; 38: D255-D266.
9. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res 2012; 40: D841-D846.
10. Antonov AV. BioProfiling.de: Analytical web portal for high-Throughput cell biology. Nucleic Acids Res 2011; 39: W323-W327.
11. Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149: 1284-1297.
12. Burgess DJ. Stem cells. Antipsychotic to anticancer agent? Nat Rev Cancer 2012; 12: 452-453.
13. Strobl JS, Peterson VA. Tamoxifen-resistant human breast cancer cell growth: Inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. J Pharmacol Exp Ther 1992; 263: 186-193.
14. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229-237.
15. Coombes RC, Perez D, Gazet JC, Ford HT, Powles TJ. Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 1983; 10: 194-195.
16. Catania C, De Pas TM, Pelosi G, Manzotti M, Adamoli L, Nolè F et al. Erlotinib-induced breast cancer regression. Ann Pharmacother 2006; 40: 2043-2047.
17. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008; 26: 897-906.
18. Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM et al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; 30: 1484-1491.
19. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-1021.
20. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
21. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 2012; 30: 921-929.
22. Zhai L, Zamani A, Liu X, Wang Y, Maxuitenko Y, Alvarez R et al. Abstract 3727: Targeting autotaxin to reduce chemotherapy resistance in ovarian cancer. Cancer Res 2012; 72, Supplement 1.
23. Park S, Gwak J, Cho M, Song T, Won J, Kim DE et al. Hexachlorophene inhibits Wnt/betacatenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 2006; 70: 960-966.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
25. Lamb J. The Connectivity Map: A new tool for biomedical research. Nature reviews. Cancer 2007; 7: 54-60.
26. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al. NCBI GEO: Archive for functional genomics data sets-10 years on. Nucleic Acids Res 2011; 39: D1005-D1010.
27. Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO. MIRUMIR: An online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ 2013; 20: 367.
28. Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA. PPISURV: A novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome. Oncogene; e-pub ahead of print 30 May 2013; doi:10.1038/ onc.2013.119.
29. D H, T F. A class of rank test procedures for censored survival data. Biometrika 1982; 69: 553-566.
30. Antonov AV, Dietmann S, Wong P, Mewes HW. TICL-A web tool for network-based interpretation of compound lists inferred by high-Throughput metabolomics. FEBS J 2009; 276: 2084-2094.
31. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine 1990; 9: 811-818.